Stockfacts
Use CasesDocsPricing
Log inSign up free
OverviewFinancialsTrendsTranscriptsOptionsShortsInstitutionsInsidersCorporate ActionsSEC Filings
Stockfacts

EOD US-equity data for investors and AI agents

Data is end-of-day, not real-time, and not investment advice

Use CasesDashboard

IKT

Inhibikase Therapeutics, Inc.

CIK 0001750149 · Nasdaq

NasdaqHealth CareBiological Products, (No Diagnostic Substances)
$2.39
↑ 0.04 (1.70%)
as of Aug 21, 2026
End-of-day close, not real-time intraday
Live price (Google Finance) ↗
Overall read: NeutralOverall score · based on 3/4 lenses
FundamentalsOwnershipTechnicalsOptions

Bullish: Ownership, Technicals; Risks: Fundamentals; Excluded: Options (no data)

Key stats

Market Cap
$333.49M
P/E Ratio
-5.50
EPS
-0.49
Dividend Yield
Not covered
52W Position
88%
Beta
1.63

Valuation multiples

Fwd P/E
Not covered
PEG
Not covered
P/B
2.18
P/S
Not covered
EV/Revenue
Not covered
ROE
-39.5%
Valuation data covers 8,711/9,697 US-listed stocks (89.8%).

Price · 1Y

250 trading days

End-of-day close, not real-time intraday

52-Week RangePosition 88%
$1.33$2.53

Latest Financials

2025-12-31 FY
Revenue
–
Net Income
-$48.26M
Total Assets
$181.20M
Free Cash Flow
-$27.80M

Recent news